Results 151 to 160 of about 1,436,444 (347)
Analysis of lipopolysaccharide antigens of Treponema hyodysenteriae [PDF]
, 1989 Lipopolysaccharide (LPS) extracts obtained from Treponema hyodysenteriae of serogroups A, B, D and E, and from T. innocens were examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), silver-staining, and immunoblotting with hyperimmune rabbit ...
Combs, B., Hampson, D.J., Mhoma, J.R.L.
core
Arthritis &Rheumatology, EarlyView.Objective The hematopoietic system maintains homeostasis by balancing myeloid and lymphoid cell production in the bone marrow (BM). In response to increased hematopoietic demand, extramedullary hematopoiesis (EMH) may occur in nonlymphoid organs. We investigated the role of EMH and kidney‐resident hematopoietic stem and progenitor cells (HSPCs) in ...
Hansol Yi +9 more
wiley +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Arthritis &Rheumatology, EarlyView.Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors
MedComm – Future MedicineIn the realm of malignant tumor treatment, particularly regarding hematologic malignancies, chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has witnessed remarkable advancements in recent years.
Yashang Zheng +3 more
doaj +1 more source
mAbsRedirection of T lymphocytes toward cancer cells has been one of the most promising treatment concepts in oncology developed over the past years and leading to multiple regulatory approvals for both adoptive cell therapy (ACT) and T-cell-engaging ...
Martin Hofmann +16 more
doaj +1 more source
CAR-T cell therapy for cancer: current challenges and future directions
Signal Transduction and Targeted TherapyChimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells.
I. Zugasti +9 more
semanticscholar +1 more source
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma? [PDF]
About one third of patients with diffuse large B-cell lymphoma (DLBCL) have a relapsing/refractory (R/R) disease after first line chemo-immunotherapy, with particularly poor outcomes observed in patients with primary refractory disease and early relapse.
de Ramon Ortiz, Carmen +9 more
core +1 more source
Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease
Arthritis &Rheumatology, EarlyView.Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg +2 more
wiley +1 more source
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Frontiers in PediatricsClinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies.
Shuto Negishi +10 more
doaj +1 more source